We came across a bullish thesis on BioAge Labs, Inc. (NASDAQ:BIOA) on Value Investing Subreddit Page by value1024. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc. (NASDAQ:BIOA)'s share was trading at $5.88 as of Dec 26^th.

A clinical-stage biopharmaceutical company's boardroom, emphasizing the importance of decision-making for the lead candidate development of a once-daily oral tablet.

BioAge Labs (NASDAQ:BIOA), a recent IPO in the biotech sector, has experienced significant volatility, dropping 75% from its $20 debut to around $6 last week. Despite the lack of revenue, the company maintains a $220M market cap and boasts over $9 per share in cash, providing runway until 2029. The sharp decline was driven by the termination of a clinical trial for its Azelaprag obesity drug, developed in collaboration with Eli Lilly, leading to investor concerns. However, the market seems to have misunderstood BIOA’s broader potential, as the company is far from a single-drug entity.

BIOA recently announced a transformative partnership with Novartis, a global pharmaceutical giant with over $45B in annual sales. The collaboration aims to discover therapies for age-related diseases and includes $20M in upfront payments and research funding, along with up to $530M in potential milestone payments. This deal underscores Novartis's confidence in BIOA’s proprietary platform, which leverages exclusive access to longitudinal human aging cohorts spanning up to 50 years. This dataset, combined with advanced AI and machine learning, identifies determinants of healthy lifespan, positioning BIOA as a key player in therapeutic discovery. The partnership could lead to further integration or even an acquisition, although BIOA’s substantial cash reserves make an early buyout unlikely.

The market’s initial reaction overlooked the strategic value of BIOA’s platform and data assets, which are critical for advancing research in age-related diseases. Investors such as Hunterbrook Capital have recognized this mispricing, as reflected in increased stock demand and strong performance last week. The collaboration with Novartis validates BIOA’s approach, providing a significant cash infusion and aligning it with a top-tier partner.

At current levels, BIOA presents a compelling risk-reward profile, combining substantial cash reserves, cutting-edge data capabilities, and a high-profile partnership. The stock is positioned to attract institutional interest, making it a potential multibagger as its platform gains recognition. While past setbacks have overshadowed its strengths, BIOA now offers a unique opportunity for investors seeking undervalued assets with transformative growth potential.

BioAge Labs, Inc. (NASDAQ:BIOA) is not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held BIOA at the end of the third quarter which was 0 in the previous quarter. While we acknowledge the risk and potential of BIOA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than BIOA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article was originally published at Insider Monkey.